A bill has been introduced to Parliament today that will increase penalties for makers and suppliers of synthetic drugs while giving police more discretion to deal with users.
Police Minister Stuart Nash and Health Minister David Clark announced last year that the Misuse of Drugs Amendment Bill would target suppliers but allow police to use their discretion to prosecute users or direct them to health services.
The Bill also makes the two main synthetics, 5F-ADB and AMB-Fubinaca, Class A drugs.
"Our current approach has failed. We need to treat drug use as a health issue and that's exactly what this Bill does," Clark said in a statement.
"We also want people caught up in the web of addiction to get the support they need to get off drugs. We don't want to ruin lives by putting people in jail at a cost to taxpayers of $110,000 a year when we can help them to get the treatment they need."
Nash said the law change reaffirmed the approach currently used by police to exercise discretion about whether to prosecute.
"Every day, frontline police make decisions about whether to prosecute in areas like road policing, shoplifting and possession of drugs for personal use. Police support these changes to the Misuse of Drugs Act, which affirm a practice already in place.
Nash said an organised crime operation this year had resulted in 32 referrals to addiction services in the greater Auckland area, and a programme in Northland had resulted in police referring 257 people to addiction treatment.
"Police are now developing comprehensive training for officers to enable them to successfully implement the changes and are drawing up guidance for health-based referrals," Nash said in a statement.
"A health-based approach recognises we cannot arrest our way out of our drug abuse problems. Many of those with addictions or dependence issues need treatment or education about harm reduction.
As well as the reclassification of AMB Fubinaca and 5F-ABD as Class A, a new classification, Class C1, will be created to give police greater search and seizure powers for other new and emerging drugs.